A central database jointly developed by Glaxo Group Research in the United Kingdom and Glaxo Inc in the United States is the basis of the Glaxo approach. The system has a wide scope and a variety of reporting functions including the standard regulatory report forms (FDA 1639, CSM yellow form, and CIOMS form). The system uses inhouse software and modified standard dictionaries with data entry direct or via a PC. The system is described and the key features discussed.
DobbsJH. Exchange of worldwide safety surveillance data via an international computer database. Drug Inf J. 1988;22: 71–74.
2.
DobbsJH. A pilot study of electronic submission of periodic reports to the FDA: Flexible diskette submission — Glaxo program development. Drug Inf J. 1988;22: 59–60.
3.
World Health Organization.Manual of the International Statistical Classification of Diseases, Injuries, and Causes of death, 9th rev. (ICD-9), vols. 1 and 2. Geneva: WHO; 1975.
4.
TalbotJCC. The collection, storage, retrieval and management of adverse drug reaction data. In: StephensMDB ed. The detection of new adverse drug reactions, 2nd ed.London: MacMillan; 1988;216–243.
